Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Kiniksa sets Phase 2/3 trial for heart drug KPL-387 | 1 | Investing.com | ||
Do | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | 38 | GlobeNewswire (Europe) | - KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast... ► Artikel lesen | |
Di | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | 1 | SEC Filings | ||
KINIKSA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
30.04. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces GRAMMY Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis | 1 | GlobeNewswire (USA) | ||
29.04. | Kiniksa Pharmaceuticals International, plc - 10-Q, Quarterly Report | - | SEC Filings | ||
29.04. | Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance | 3 | Seeking Alpha | ||
29.04. | Kiniksa Pharmaceuticals International, plc GAAP EPS of $0.11 beats by $0.09, revenue of $137.7M beats by $5.99M | 1 | Seeking Alpha | ||
29.04. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution | 300 | GlobeNewswire (Europe) | - ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387... ► Artikel lesen | |
28.04. | Examining the Future: Kiniksa Pharmaceuticals' Earnings Outlook | 1 | Benzinga.com | ||
24.04. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 | 1 | GlobeNewswire (USA) | ||
23.04. | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | 1 | SEC Filings | ||
06.03. | Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst | 5 | Benzinga.com | ||
25.02. | Kiniksa Pharmaceuticals International, plc - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
25.02. | Kiniksa Pharmaceuticals International, plc - 10-K, Annual Report | - | SEC Filings | ||
25.02. | Kiniksa adds to Sjögren's exodus with trial termination, axes AstraZeneca asset | 5 | FierceBiotech | ||
25.02. | Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 | 2 | Investing.com | ||
25.02. | Kiniksa Pharmaceuticals, Ltd. Q4 Earnings Summary | - | RTTNews | ||
25.02. | Kiniksa startet Phase-2/3-Studie für Herzmedikament KPL-387 | - | Investing.com Deutsch | ||
25.02. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy | 327 | GlobeNewswire (Europe) | - Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa... ► Artikel lesen | |
25.02. | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution | 306 | GlobeNewswire (Europe) | - ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively -- ARCALYST 2025 net product revenue expected to be $560 - $580 million --... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,85 | +0,62 % | BioNTech - Milliardenschwerer Deal für Krebsmedikament | ||
BB BIOTECH | 32,500 | 0,00 % | BB Biotech - Optimistic about biotech's long-term prospects | During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution... ► Artikel lesen | |
CUREVAC | 3,860 | -1,13 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
MODERNA | 22,940 | -2,59 % | Die US-Regierung streicht Moderna ohne erkennbaren Druck etliche Millionen an Fördergeldern für Pandemie-Bekämpfung | Es liegt wohl in der Natur des Menschen, sich über alles nur Erdenkliche zu streiten. Allerdings dürfte es auch Themen geben, bei denen weitgehend Einigkeit herrscht. Dazu gehört die Bekämpfung von... ► Artikel lesen | |
AMGEN | 252,90 | +0,74 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NOVAVAX | 6,097 | -0,41 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
BIOGEN | 114,10 | +0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
REGENERON PHARMACEUTICALS | 422,60 | +0,07 % | Aktien New York Ausblick: Anleger scheuen vor dem Wochenende das Risiko | NEW YORK (dpa-AFX) - Am US-Aktienmarkt zeichnen sich am Freitag moderate Verluste ab. Das Hin und Her im US-Zollstreit hat zwar einen großen Teil seines Schreckens verloren. Investoren reagieren längst... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
VIKING THERAPEUTICS | 24,045 | +1,67 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
INTELLIA THERAPEUTICS | 6,570 | -0,67 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 9,610 | +0,15 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
TEMPUS AI | 52,52 | +2,34 % | Opening Bell: Constellation Energy, Vistra, Netflix, Applied Digital, Steel Dyn., Pony.ai, Tempus AI | Zum Wochenauftakt schwankten die US-Börsen zwischen neuen Zolldrohungen und der Hoffnung auf sinkende Zinsen. Zwar sorgte US-Präsident Trumps verschärfte Rhetorik im Handelsstreit mit China zunächst... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 35,000 | +2,13 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,208 | +0,50 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating |